Chronic Heart Failure Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Coverage : Surgery (Coronary revascularization, Cardiac resynchronization, Heart valve replacement, Coronary artery bypass grafting, Heart transplant); Drug Class (Anti-clotting, Antiplatelet medicines, Anticoagulant medicines, Angiotensin converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARB), Statins, Nitrates, Diuretics, Beta blockers, If Channel Blocker, Vaccines); Medical Devices (Implantable left ventricular assist device (LVAD), Biventricular pacemaker, Implantable cardioverter-defibrillators (ICDs), Continuous positive air pressure device (CPAP), Bi-level positive air pressure device (BiPAP), Heart pumps), and by Geography

Report Code: TIPRE00018100 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

A chronic progressive condition that affects the pumping power of heart muscles is chronic heart failure. While sometimes referred to as "heart failure," it refers explicitly to the process in which fluid builds up around the heart and causes it to pump inefficiently. Heart failure treatment normally attempts to control the symptoms for as long as possible and to delay the progression of the disease. Treatment plan may include lifestyle changes, medications, and devices and surgical procedures.

MARKET DYNAMICS

Factors driving the growth of the chronic heart failure treatment market are the growing prevalence of cardiovascular diseases (CVD), coupled with increasing technological advanced products. However, the high cost of treatment is expected to hamper the growth of the market. Moreover, favorable reimbursement policies and rising geriatric population is anticipated to boost the market growth.

MARKET SCOPE

The "Chronic Heart Failure Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of chronic heart failure treatment market with detailed market segmentation by surgery, drug class, and medical devices. The chronic heart failure treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in chronic heart failure treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The chronic heart failure treatment market is segmented on the basis of surgery, drug class, and medical devices. Based on surgery, the market is segmented as Coronary revascularization, cardiac resynchronization, heart valve replacement, coronary artery bypass grafting, and heart transplant. On the basis of drug class, the market is categorized as anti-clotting, antiplatelet medicines, anticoagulant medicines, Angiotensin converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARB), statins, nitrates, statins, If Channel Blocker, and vaccines. Antiplatelet medicines categorized as Clopidogrel, Prasugrel, and Ticagrelor. On the basis of medical devices, the market is categorized as Implantable left ventricular assist device (LVAD), Biventricular pacemaker, Implantable cardioverter-defibrillators (ICDs), Continuous positive air pressure device (CPAP), Bi-level positive air pressure device (BiPAP), and Heart pumps.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the chronic heart failure treatment market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The chronic heart failure treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting chronic heart failure treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the chronic heart failure treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the chronic heart failure treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from chronic heart failure treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for chronic heart failure treatment in the global market. Below mentioned is the list of few companies engaged in the chronic heart failure treatment market.

The report also includes the profiles of key players in chronic heart failure treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Stanley Pharmaceuticals
  •  New Haven Pharmaceuticals, Inc.
  •  Boston Scientific Corporation
  •  HeartWare International, Inc.
  •  Pfizer, GlaxoSmithKline plc
  •  Novartis International AG
  •  Biovail Corporation
  •  Bristol-Myers Squibb Company
  •  Merck Sharp & Dohme
  •  AstraZeneca

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Heart Failure Treatment Market - By Surgery
1.3.2 Chronic Heart Failure Treatment Market - By Drug Class
1.3.3 Chronic Heart Failure Treatment Market - By Medical Devices
1.3.4 Chronic Heart Failure Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHRONIC HEART FAILURE TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHRONIC HEART FAILURE TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CHRONIC HEART FAILURE TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC HEART FAILURE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. CHRONIC HEART FAILURE TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHRONIC HEART FAILURE TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - SURGERY
7.1. OVERVIEW
7.2. SURGERY MARKET FORECASTS AND ANALYSIS
7.3. CORONARY REVASCULARIZATION
7.3.1. Overview
7.3.2. Coronary revascularization Market Forecast and Analysis
7.4. CARDIAC RESYNCHRONIZATION
7.4.1. Overview
7.4.2. Cardiac resynchronization Market Forecast and Analysis
7.5. HEART VALVE REPLACEMENT
7.5.1. Overview
7.5.2. Heart valve replacement Market Forecast and Analysis
7.6. CORONARY ARTERY BYPASS GRAFTING
7.6.1. Overview
7.6.2. Coronary artery bypass grafting Market Forecast and Analysis
7.7. HEART TRANSPLANT
7.7.1. Overview
7.7.2. Heart transplant Market Forecast and Analysis
8. CHRONIC HEART FAILURE TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-CLOTTING
8.3.1. Overview
8.3.2. Anti-clotting Market Forecast and Analysis
8.4. ANTIPLATELET MEDICINES
8.4.1. Overview
8.4.2. Antiplatelet medicines Market Forecast and Analysis
8.4.3. Clopidogrel Market
8.4.3.1. Overview
8.4.3.2. Clopidogrel Market Forecast and Analysis
8.4.4. Prasugrel Market
8.4.4.1. Overview
8.4.4.2. Prasugrel Market Forecast and Analysis
8.4.5. Ticagrelor Market
8.4.5.1. Overview
8.4.5.2. Ticagrelor Market Forecast and Analysis
8.5. ANTICOAGULANT MEDICINES
8.5.1. Overview
8.5.2. Anticoagulant medicines Market Forecast and Analysis
8.6. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
8.6.1. Overview
8.6.2. Angiotensin converting enzyme (ACE) inhibitors Market Forecast and Analysis
8.6.3. Market
8.6.3.1. Overview
8.6.3.2. Market Forecast and Analysis
8.7. ANGIOTENSIN II RECEPTOR BLOCKERS (ARB)
8.7.1. Overview
8.7.2. Angiotensin II receptor blockers (ARB) Market Forecast and Analysis
8.8. STATINS
8.8.1. Overview
8.8.2. Statins Market Forecast and Analysis
8.9. NITRATES
8.9.1. Overview
8.9.2. Nitrates Market Forecast and Analysis
8.10. DIURETICS
8.10.1. Overview
8.10.2. Diuretics Market Forecast and Analysis
8.11. BETA BLOCKERS
8.11.1. Overview
8.11.2. Beta blockers Market Forecast and Analysis
8.12. IF CHANNEL BLOCKER
8.12.1. Overview
8.12.2. If Channel Blocker Market Forecast and Analysis
8.13. VACCINES
8.13.1. Overview
8.13.2. Vaccines Market Forecast and Analysis
9. CHRONIC HEART FAILURE TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - MEDICAL DEVICES
9.1. OVERVIEW
9.2. MEDICAL DEVICES MARKET FORECASTS AND ANALYSIS
9.3. IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE (LVAD)
9.3.1. Overview
9.3.2. Implantable left ventricular assist device (LVAD) Market Forecast and Analysis
9.4. BIVENTRICULAR PACEMAKER
9.4.1. Overview
9.4.2. Biventricular pacemaker Market Forecast and Analysis
9.5. IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS (ICDS)
9.5.1. Overview
9.5.2. Implantable cardioverter-defibrillators (ICDs) Market Forecast and Analysis
9.6. CONTINUOUS POSITIVE AIR PRESSURE DEVICE (CPAP)
9.6.1. Overview
9.6.2. Continuous positive air pressure device (CPAP) Market Forecast and Analysis
9.7. BI-LEVEL POSITIVE AIR PRESSURE DEVICE (BIPAP)
9.7.1. Overview
9.7.2. Bi-level positive air pressure device (BiPAP) Market Forecast and Analysis
9.8. HEART PUMPS
9.8.1. Overview
9.8.2. Heart pumps Market Forecast and Analysis
10. CHRONIC HEART FAILURE TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Chronic Heart Failure Treatment Market Overview
10.1.2 North America Chronic Heart Failure Treatment Market Forecasts and Analysis
10.1.3 North America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Surgery
10.1.4 North America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Drug Class
10.1.5 North America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Medical Devices
10.1.6 North America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Chronic Heart Failure Treatment Market
10.1.6.1.1 United States Chronic Heart Failure Treatment Market by Surgery
10.1.6.1.2 United States Chronic Heart Failure Treatment Market by Drug Class
10.1.6.1.3 United States Chronic Heart Failure Treatment Market by Medical Devices
10.1.6.2 Canada Chronic Heart Failure Treatment Market
10.1.6.2.1 Canada Chronic Heart Failure Treatment Market by Surgery
10.1.6.2.2 Canada Chronic Heart Failure Treatment Market by Drug Class
10.1.6.2.3 Canada Chronic Heart Failure Treatment Market by Medical Devices
10.1.6.3 Mexico Chronic Heart Failure Treatment Market
10.1.6.3.1 Mexico Chronic Heart Failure Treatment Market by Surgery
10.1.6.3.2 Mexico Chronic Heart Failure Treatment Market by Drug Class
10.1.6.3.3 Mexico Chronic Heart Failure Treatment Market by Medical Devices
10.2. EUROPE
10.2.1 Europe Chronic Heart Failure Treatment Market Overview
10.2.2 Europe Chronic Heart Failure Treatment Market Forecasts and Analysis
10.2.3 Europe Chronic Heart Failure Treatment Market Forecasts and Analysis - By Surgery
10.2.4 Europe Chronic Heart Failure Treatment Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Chronic Heart Failure Treatment Market Forecasts and Analysis - By Medical Devices
10.2.6 Europe Chronic Heart Failure Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Chronic Heart Failure Treatment Market
10.2.6.1.1 Germany Chronic Heart Failure Treatment Market by Surgery
10.2.6.1.2 Germany Chronic Heart Failure Treatment Market by Drug Class
10.2.6.1.3 Germany Chronic Heart Failure Treatment Market by Medical Devices
10.2.6.2 France Chronic Heart Failure Treatment Market
10.2.6.2.1 France Chronic Heart Failure Treatment Market by Surgery
10.2.6.2.2 France Chronic Heart Failure Treatment Market by Drug Class
10.2.6.2.3 France Chronic Heart Failure Treatment Market by Medical Devices
10.2.6.3 Italy Chronic Heart Failure Treatment Market
10.2.6.3.1 Italy Chronic Heart Failure Treatment Market by Surgery
10.2.6.3.2 Italy Chronic Heart Failure Treatment Market by Drug Class
10.2.6.3.3 Italy Chronic Heart Failure Treatment Market by Medical Devices
10.2.6.4 Spain Chronic Heart Failure Treatment Market
10.2.6.4.1 Spain Chronic Heart Failure Treatment Market by Surgery
10.2.6.4.2 Spain Chronic Heart Failure Treatment Market by Drug Class
10.2.6.4.3 Spain Chronic Heart Failure Treatment Market by Medical Devices
10.2.6.5 United Kingdom Chronic Heart Failure Treatment Market
10.2.6.5.1 United Kingdom Chronic Heart Failure Treatment Market by Surgery
10.2.6.5.2 United Kingdom Chronic Heart Failure Treatment Market by Drug Class
10.2.6.5.3 United Kingdom Chronic Heart Failure Treatment Market by Medical Devices
10.2.6.6 Rest of Europe Chronic Heart Failure Treatment Market
10.2.6.6.1 Rest of Europe Chronic Heart Failure Treatment Market by Surgery
10.2.6.6.2 Rest of Europe Chronic Heart Failure Treatment Market by Drug Class
10.2.6.6.3 Rest of Europe Chronic Heart Failure Treatment Market by Medical Devices
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Chronic Heart Failure Treatment Market Overview
10.3.2 Asia-Pacific Chronic Heart Failure Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Chronic Heart Failure Treatment Market Forecasts and Analysis - By Surgery
10.3.4 Asia-Pacific Chronic Heart Failure Treatment Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Chronic Heart Failure Treatment Market Forecasts and Analysis - By Medical Devices
10.3.6 Asia-Pacific Chronic Heart Failure Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Chronic Heart Failure Treatment Market
10.3.6.1.1 Australia Chronic Heart Failure Treatment Market by Surgery
10.3.6.1.2 Australia Chronic Heart Failure Treatment Market by Drug Class
10.3.6.1.3 Australia Chronic Heart Failure Treatment Market by Medical Devices
10.3.6.2 China Chronic Heart Failure Treatment Market
10.3.6.2.1 China Chronic Heart Failure Treatment Market by Surgery
10.3.6.2.2 China Chronic Heart Failure Treatment Market by Drug Class
10.3.6.2.3 China Chronic Heart Failure Treatment Market by Medical Devices
10.3.6.3 India Chronic Heart Failure Treatment Market
10.3.6.3.1 India Chronic Heart Failure Treatment Market by Surgery
10.3.6.3.2 India Chronic Heart Failure Treatment Market by Drug Class
10.3.6.3.3 India Chronic Heart Failure Treatment Market by Medical Devices
10.3.6.4 Japan Chronic Heart Failure Treatment Market
10.3.6.4.1 Japan Chronic Heart Failure Treatment Market by Surgery
10.3.6.4.2 Japan Chronic Heart Failure Treatment Market by Drug Class
10.3.6.4.3 Japan Chronic Heart Failure Treatment Market by Medical Devices
10.3.6.5 South Korea Chronic Heart Failure Treatment Market
10.3.6.5.1 South Korea Chronic Heart Failure Treatment Market by Surgery
10.3.6.5.2 South Korea Chronic Heart Failure Treatment Market by Drug Class
10.3.6.5.3 South Korea Chronic Heart Failure Treatment Market by Medical Devices
10.3.6.6 Rest of Asia-Pacific Chronic Heart Failure Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Chronic Heart Failure Treatment Market by Surgery
10.3.6.6.2 Rest of Asia-Pacific Chronic Heart Failure Treatment Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Chronic Heart Failure Treatment Market by Medical Devices
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Chronic Heart Failure Treatment Market Overview
10.4.2 Middle East and Africa Chronic Heart Failure Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Chronic Heart Failure Treatment Market Forecasts and Analysis - By Surgery
10.4.4 Middle East and Africa Chronic Heart Failure Treatment Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Chronic Heart Failure Treatment Market Forecasts and Analysis - By Medical Devices
10.4.6 Middle East and Africa Chronic Heart Failure Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Chronic Heart Failure Treatment Market
10.4.6.1.1 South Africa Chronic Heart Failure Treatment Market by Surgery
10.4.6.1.2 South Africa Chronic Heart Failure Treatment Market by Drug Class
10.4.6.1.3 South Africa Chronic Heart Failure Treatment Market by Medical Devices
10.4.6.2 Saudi Arabia Chronic Heart Failure Treatment Market
10.4.6.2.1 Saudi Arabia Chronic Heart Failure Treatment Market by Surgery
10.4.6.2.2 Saudi Arabia Chronic Heart Failure Treatment Market by Drug Class
10.4.6.2.3 Saudi Arabia Chronic Heart Failure Treatment Market by Medical Devices
10.4.6.3 U.A.E Chronic Heart Failure Treatment Market
10.4.6.3.1 U.A.E Chronic Heart Failure Treatment Market by Surgery
10.4.6.3.2 U.A.E Chronic Heart Failure Treatment Market by Drug Class
10.4.6.3.3 U.A.E Chronic Heart Failure Treatment Market by Medical Devices
10.4.6.4 Rest of Middle East and Africa Chronic Heart Failure Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Chronic Heart Failure Treatment Market by Surgery
10.4.6.4.2 Rest of Middle East and Africa Chronic Heart Failure Treatment Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Chronic Heart Failure Treatment Market by Medical Devices
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Chronic Heart Failure Treatment Market Overview
10.5.2 South and Central America Chronic Heart Failure Treatment Market Forecasts and Analysis
10.5.3 South and Central America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Surgery
10.5.4 South and Central America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Medical Devices
10.5.6 South and Central America Chronic Heart Failure Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Chronic Heart Failure Treatment Market
10.5.6.1.1 Brazil Chronic Heart Failure Treatment Market by Surgery
10.5.6.1.2 Brazil Chronic Heart Failure Treatment Market by Drug Class
10.5.6.1.3 Brazil Chronic Heart Failure Treatment Market by Medical Devices
10.5.6.2 Argentina Chronic Heart Failure Treatment Market
10.5.6.2.1 Argentina Chronic Heart Failure Treatment Market by Surgery
10.5.6.2.2 Argentina Chronic Heart Failure Treatment Market by Drug Class
10.5.6.2.3 Argentina Chronic Heart Failure Treatment Market by Medical Devices
10.5.6.3 Rest of South and Central America Chronic Heart Failure Treatment Market
10.5.6.3.1 Rest of South and Central America Chronic Heart Failure Treatment Market by Surgery
10.5.6.3.2 Rest of South and Central America Chronic Heart Failure Treatment Market by Drug Class
10.5.6.3.3 Rest of South and Central America Chronic Heart Failure Treatment Market by Medical Devices
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL CHRONIC HEART FAILURE TREATMENT MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CHRONIC HEART FAILURE TREATMENT MARKET, KEY COMPANY PROFILES
13.1. STANLEY PHARMACEUTICALS
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. NEW HAVEN PHARMACEUTICALS, INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BOSTON SCIENTIFIC CORPORATION
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. HEARTWARE INTERNATIONAL, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PFIZER, GLAXOSMITHKLINE PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVARTIS INTERNATIONAL AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BIOVAIL CORPORATION
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BRISTOL-MYERS SQUIBB COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. MERCK SHARP AND DOHME
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. ASTRAZENECA
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Stanley Pharmaceuticals
2. New Haven Pharmaceuticals, Inc.
3. Boston Scientific Corporation
4. HeartWare International, Inc.
5. Pfizer, GlaxoSmithKline plc
6. Novartis International AG
7. Biovail Corporation
8. Bristol-Myers Squibb Company
9. Merck Sharp & Dohme
10. AstraZeneca
TIPRE00018100
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking